Allarity Therapeutics, Inc.
ALLR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $6 | $7 | $7 | $14 |
| G&A Expenses | $11 | $10 | $10 | $12 |
| SG&A Expenses | $11 | $10 | $10 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10 | $0 | $18 | $0 |
| Operating Expenses | $27 | $17 | $34 | $27 |
| Operating Income | -$27 | -$17 | -$34 | -$27 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $5 | $17 | $0 |
| Pre-Tax Income | -$25 | -$12 | -$18 | -$27 |
| Tax Expense | -$0 | $0 | -$2 | $0 |
| Net Income | -$25 | -$12 | -$16 | -$27 |
| % Margin | – | – | – | – |
| EPS | -15.791 | -6,153.264 | -1,856,055 | -3,520,104 |
| % Growth | 99.7% | 99.7% | 47.3% | – |
| EPS Diluted | -15.791 | -6,153.264 | -1,856,055 | -3,520,104 |
| Weighted Avg Shares Out | 2 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 2 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$24 | -$11 | -$17 | -$26 |
| % Margin | – | – | – | – |